Arch Therapeutics to Present at the Biotech Showcase(TM) 2016 Conference on January 12th 2016

FRAMINGHAM, MA--(Marketwired - Jan 4, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™ ("AC5TM"), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that it would be featured as a presenting company at The Biotech Showcase™ 2016 Conference taking place from January 11-13, 2016. The conference will be held at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California.

Chief Executive Officer, Terrence W. Norchi, MD, is scheduled to present on Tuesday, January 12, 2016 at 11:00 AM PST. Dr. Norchi and Richard Davis, Chief Financial Officer, will be available to participate in meetings with the investment community during the conference.

If you are an investor and wish to attend the Company's presentation or a schedule a meeting at the conference, please click on the following link: http://www.ebdgroup.com/bts/registration/index.php.

A live webcast of the presentation may be accessed by visiting http://edge.media-server.com/m/p/vndca8fk. Additionally, the presentation will be made available for download at http://ir.archtherapeutics.com.

About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures and is intended to be regulated as a medical device. Find out more at www.archtherapeutics.com.

About The Biotech Showcase 2016 Conference
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.